UroGen Pharma Ltd
URGN
27.65
-4.08
-12.86%
UroGen Pharma Ltd
US · URGN
#2773 by market cap
Listed 2017
27.65
-4.08
-12.86%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 16 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.4 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 101.87% +2.35pp
- Institutions
- 246 +16
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund36.10%
Hedge Fund31.83%
Public Company19.06%
VC/PE Fund9.15%
Private Company4.40%
Individual/Insider1.89%
Government Pension Fund1.07%
Insurance Company0.21%
Other2.09%
Top holders as of 2026-06-30
RTW Investments, LP
9.26% · 4.54M sh
The Toronto-Dominion Bank
6.87% · 3.37M sh
BlackRock
6.24% · 3.06M sh
Kynam Capital Management, LP
4.96% · 2.43M sh
Jefferies Financial Group Inc.
4.48% · 2.20M sh
Morgan Stanley
4.43% · 2.17M sh
Morgan Stanley Investment Management Inc.
4.43% · 2.17M sh
SG Americas Securities, LLC
4.19% · 2.05M sh
American Century Investment Management
3.45% · 1.69M sh
Acorn Bioventures
3.41% · 1.67M sh
Point72 Asset Management, L.P.
3.11% · 1.53M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Arie Belldegrun | Independent Chairperson | 0.83% |
| Elizabeth Barrett | Chief Executive Officer | 0.67% |
| Mark Schoenberg | Chief Medical Officer | 0.12% |
| Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | 0.11% |
| Dong Kim | Former Chief Financial Officer | 0.09% |
| Fred Cohen | Former Independent Director | 0.03% |
| James Robinson | Independent Director | 0.02% |
| Christopher Degnan | Chief Financial Officer | 0.01% |
| Stuart Holden | Independent Director | 0.00% |
| Cynthia Butitta | Independent Director | 0.00% |
| Leana Wen | Independent Director | 0.00% |
| Daniel Wildman | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-07 | Christopher Degnan | Chief Financial Officer | Derivative Exercise and Sale | -2,202 | $36.69 |
| 2026-10-07 | Christopher Degnan | Chief Financial Officer | Derivative Exercise and Retained | +2,281 | -- |
| 2026-09-07 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Sale | -871 | $42.92 |
| 2026-09-07 | Mark Schoenberg | Chief Medical Officer | Intent to Sell (Form 144) | -871 | $44.09 |
| 2026-09-07 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Sale | -1,519 | $42.54 |
| 2026-09-07 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Intent to Sell (Form 144) | -1,519 | $44.09 |
| 2026-09-06 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Retained | +796 | -- |
| 2026-09-06 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Retained | +1,815 | -- |
| 2026-08-25 | James Robinson | Independent Director | Derivative Exercise and Retained | +2,000 | -- |
| 2026-08-19 | Mark Schoenberg | Chief Medical Officer | Open Market Disposition | -60,677 | $47.05 |
| 2026-07-08 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $40.00 |
| 2026-06-21 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Stuart Holden | Independent Director | Other Derivative Acquisition | +20,000 | $34.99 |
| 2026-06-21 | Arie Belldegrun | Independent Chairperson | Other Derivative Acquisition | +20,000 | $34.99 |
| 2026-06-21 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $35.01 |
| 2026-06-21 | James Robinson | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | James Robinson | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
UroGen Pharma Ltd discussion 0 comments